Free Trial

FibroBiologics Q2 2024 Earnings Report

FibroBiologics logo
$0.95 -0.07 (-6.86%)
As of 03/28/2025 04:00 PM Eastern

FibroBiologics EPS Results

Actual EPS
-$0.09
Consensus EPS
-$0.09
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

FibroBiologics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

FibroBiologics Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

Remove Ads

FibroBiologics Earnings Headlines

FibroBiologics Announces 2025 Annual Meeting of Stockholders
Elon’s ‘Strike Squad’ sends these 9 stocks soaring?
Elon Musk's DOGE 'strike squad' just revealed it's speeding up the rollout of a radical technology across the federal government. And that's creating a huge buying opportunity for the stocks involved. Put simply, under Elon's watchful eye, the U.S. government is rapidly adopting AI technology. And that's sending certain stocks soaring higher.
See More FibroBiologics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like FibroBiologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on FibroBiologics and other key companies, straight to your email.

About FibroBiologics

FibroBiologics (NASDAQ:FBLG) operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.

View FibroBiologics Profile

More Earnings Resources from MarketBeat